Security
MiniMed Group, Inc. · MMED.WA
MMED.WANEOCommon stockHistorical · closed Dec 8, 2023CIK 2062583Updated Nov 2, 2026
MMED.WA price & chart
This listing closed Dec 8, 2023. Live provider charts are shown only for current listings.
Current security: MMED
About the company
We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q1 2027 | Q1 2026 | FY 2026 |
|---|---|---|---|---|---|
| ASSETS | |||||
| AssetsUSD | 4,343,000,000Source | — | 4,718,000,000Source | — | 4,630,000,000Source |
| Property, Plant and Equipment, NetUSD | 701,000,000Source | — | 736,000,000Source | — | 711,000,000Source |
| GoodwillUSD | 2,256,000,000Source | — | 2,255,000,000Source | — | 2,256,000,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 113,000,000Source | — | 100,000,000Source | — | 107,000,000Source |
| Current assets: | |||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,000,000Source | — | 207,000,000Source | — | 298,000,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 653,000,000Source | — | 180,000,000Source | — | 200,000,000Source |
| Inventory, NetUSD | 408,000,000Source | — | 356,000,000Source | — | 341,000,000Source |
| Assets, CurrentUSD | 1,108,000,000Source | — | 1,417,000,000Source | — | 1,348,000,000Source |
| Operating Lease, Right-of-Use AssetUSD | 60,000,000Source | — | 57,000,000Source | — | 52,000,000Source |
| Other Assets, NoncurrentUSD | 146,000,000Source | — | 152,000,000Source | — | 147,000,000Source |
| LIABILITIES AND EQUITY | |||||
| LiabilitiesUSD | 881,000,000Source | — | 1,098,000,000Source | — | 1,019,000,000Source |
| Stockholders’ equity: | |||||
| Preferred Stock, Value, IssuedUSD | — | — | 0Source | — | 0Source |
| Common Stock, Value, IssuedUSD | — | — | 3,000,000Source | — | 3,000,000Source |
| Additional Paid in CapitalUSD | — | — | 3,747,000,000Source | — | 3,736,000,000Source |
| Retained Earnings (Accumulated Deficit)USD | — | — | -116,000,000Source | — | -116,000,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 14,000,000Source | — | -14,000,000Source | — | -12,000,000Source |
| Stockholders' Equity Attributable to ParentUSD | 3,462,000,000Source | 3,485,000,000Source | 3,620,000,000Source | 3,537,000,000Source | 3,611,000,000Source |
| Liabilities and EquityUSD | 4,343,000,000Source | — | 4,718,000,000Source | — | 4,630,000,000Source |
| Current liabilities: | |||||
| Liabilities, CurrentUSD | 696,000,000Source | — | 782,000,000Source | — | 702,000,000Source |
| Operating Lease, Liability, CurrentUSD | 11,000,000Source | — | 9,000,000Source | — | 8,000,000Source |
| Accounts Payable, CurrentUSD | 303,000,000Source | — | 251,000,000Source | — | 163,000,000Source |
| Operating Lease, Liability, NoncurrentUSD | 50,000,000Source | — | 50,000,000Source | — | 45,000,000Source |
| Other Liabilities, NoncurrentUSD | 184,000,000Source | — | 316,000,000Source | — | 317,000,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | — | — | 0Source |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q1 2027 | Q1 2026 | FY 2026 |
|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -111,000,000Source | -7,000,000Source | 0Source | -16,000,000Source | -317,000,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | 41,000,000Source | 39,000,000Source | 156,000,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | 10,000,000Source | 9,000,000Source | 46,000,000Source |
| Changes in operating assets and liabilities: | |||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | 15,000,000Source | 30,000,000Source | 29,000,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | -50,000,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | -49,000,000Source | -141,000,000Source | -197,000,000Source |
| Cash flows from investing activities: | |||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | -41,000,000Source | -63,000,000Source | -233,000,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | — | 0Source | 10,000,000Source | 10,000,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | 41,000,000Source | 53,000,000Source | 223,000,000Source |
| Cash flows from financing activities: | |||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | 0Source | 202,000,000Source | 716,000,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | -91,000,000Source | -2,000,000Source | 287,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 10,000,000Source | 10,000,000Source | 207,000,000Source | 9,000,000Source | 298,000,000Source |
| Supplemental disclosure of cash flow information: | |||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 2,000,000Source |
| Additional Financial Items | |||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 11,000,000Source | 11,000,000Source | 10,000,000Source | 9,000,000Source | 46,000,000Source |
| Amortization of Intangible AssetsUSD | — | — | 7,000,000Source | 7,000,000Source | 6,000,000Source | 7,000,000Source | 26,000,000Source |
| DepreciationUSD | — | — | — | — | — | — | 130,000,000Source |
| Equity Method Investment, Other than Temporary ImpairmentUSD | — | — | — | — | — | — | 1,000,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | 6,000,000Source | 0Source | 2,000,000Source | -17,000,000Source | -18,000,000Source |
| GoodwillUSD | — | — | 2,256,000,000Source | — | 2,255,000,000Source | — | 2,256,000,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 12,000,000Source | 28,000,000Source | 4,000,000Source | 3,000,000Source | 128,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -119,000,000Source | -10,000,000Source | 0Source | -19,000,000Source | -333,000,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 8,000,000Source | 3,000,000Source | 0Source | 3,000,000Source | 16,000,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 0Source | 0Source | 0Source | 1,000,000Source |
| Other Operating Income (Expense), NetUSD | — | — | -45,000,000Source | 7,000,000Source | -36,000,000Source | 2,000,000Source | -221,000,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 0Source |
| Proceeds from Contributions from ParentUSD | — | — | — | — | 0Source | 202,000,000Source | 407,000,000Source |
| Restructuring CostsUSD | — | — | 138,000,000Source | 2,000,000Source | — | — | 142,000,000Source |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q1 2027 | Q1 2026 | FY 2026 |
|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 790,000,000Source | 687,000,000Source | 843,000,000Source | 723,000,000Source | 3,102,000,000Source |
| Cost of RevenueUSD | — | — | 428,000,000Source | 292,000,000Source | 378,000,000Source | 314,000,000Source | 1,422,000,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 309,000,000Source | 268,000,000Source | 312,000,000Source | 283,000,000Source | 1,183,000,000Source |
| Operating Income (Loss)USD | — | — | -100,000,000Source | 21,000,000Source | 5,000,000Source | -13,000,000Source | -190,000,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 0Source | 0Source | 0Source | 1,000,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -99,000,000Source | 21,000,000Source | 4,000,000Source | -13,000,000Source | -189,000,000Source |
| Income Tax Expense (Benefit)USD | — | — | 12,000,000Source | 28,000,000Source | 4,000,000Source | 3,000,000Source | 128,000,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 8,000,000Source | 3,000,000Source | 0Source | 3,000,000Source | 16,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -119,000,000Source | -10,000,000Source | 0Source | -19,000,000Source | -333,000,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.47Source | -0.04Source | 0Source | -0.08Source | -1.3Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.47Source | -0.04Source | 0Source | -0.08Source | -1.3Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 252,813,348Source | 252,813,348Source | 281,000,000Source | 252,800,000Source | 256,600,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 252,813,348Source | 252,813,348Source | 281,000,000Source | 252,800,000Source | 256,600,000Source |
| Additional Financial Items | |||||||
| Amortization of Intangible AssetsUSD | — | — | 7,000,000Source | 7,000,000Source | 6,000,000Source | 7,000,000Source | 26,000,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 178,000,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | 6,000,000Source | 0Source | 2,000,000Source | -17,000,000Source | -18,000,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | — | — | 362,000,000Source | 395,000,000Source | 465,000,000Source | 409,000,000Source | 1,680,000,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | -381,000,000Source |
| Other Operating Income (Expense), NetUSD | — | — | -45,000,000Source | 7,000,000Source | -36,000,000Source | 2,000,000Source | -221,000,000Source |
| Restructuring CostsUSD | — | — | 138,000,000Source | 2,000,000Source | — | — | 142,000,000Source |
Offerings
Registration 333-298914
Registration 333-292284
Underwriters: Goldman Sachs & Co. LLC, Wells Fargo Securities, LLC, Evercore Group L.L.C., Piper Sandler & Co., BTIG, LLC, William Blair & Company, L.L.C., BofA Securities, Citigroup, Morgan Stanley, BofA Securities, Inc., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, Barclays Capital Inc., Deutsche Bank Securities Inc., Mizuho Securities USA LLC
Filing attachments
tm2627653d1_ex99-1.htm · 8-K · 2026-10-16
Exhibit 99.1 MiniMed Completes Separation from Medtronic NORTHRIDGE, Calif., October 15, 2026 - MiniMed (Nasdaq: MMED) today announced the completion of its separation from Medtronic plc (“Medtronic”; NYSE: MDT), marking its first day as a fully independent company. “Today marks the completion of our separation from Medtronic and a significant milestone for MiniMed,” said Que Dallara, Chief Executive Officer of MiniMed. “We are grateful to Medtronic for its partnership and support in reachin…
Read attachment ↗